You Don’t Have to Take On
An exceptional opportunity: the VOYAGE study.
As you know, NASH is a condition in which excess fat is stored in the liver, accompanied by inflammation and liver cell damage. Over time, NASH can cause liver fibrosis (scarring) and may lead to cirrhosis or liver cancer. The VOYAGE (VK2809-202) study is researching an investigational drug called VK2809 for patients with NASH. If you are 18 to 75 years of age and have been diagnosed with NASH, you may qualify to participate.
VK2809 is thought to act like thyroid hormone, which may help the liver reduce excess fat. The purpose of the VOYAGE study is to evaluate the safety and effectiveness of this investigational drug versus placebo in patients with NASH. “Investigational” means that this drug has not been FDA approved and its use is being allowed for research purposes only.
If you qualify for the VOYAGE study and choose to participate, you will be in the study for approximately 15 months, during which you’ll be randomly assigned to receive either VK2809 or placebo. A placebo looks just like the investigational drug but contains no active medication. Neither you nor the study doctor will know which you are receiving until the end of the study, but in the case of an emergency, the study doctor can quickly find out.
All study-related office visits, medical procedures, laboratory tests, and VK2809 or placebo will be provided at no cost. Reimbursement for time and travel may also be available.
About Clinical Research
Every day, clinical research uncovers new information about medical conditions and their treatment.
If you have any questions, don’t hesitate to contact us.